- Home
- TNYA vs GALT Comparison
TNYA vs GALT Comparison
Compare TNYA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- GALT
- Stock Information
- Founded
- TNYA 2016
- GALT 2000
- Country
- TNYA United States
- GALT United States
- Employees
- TNYA N/A
- GALT N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- TNYA Health Care
- GALT Health Care
- Exchange
- TNYA Nasdaq
- GALT Nasdaq
- Market Cap
- TNYA 73.8M
- GALT 83.5M
- IPO Year
- TNYA 2021
- GALT N/A
- Fundamental
- Price
- TNYA $0.69
- GALT $2.52
- Analyst Decision
- TNYA Strong Buy
- GALT Buy
- Analyst Count
- TNYA 5
- GALT 2
- Target Price
- TNYA $8.60
- GALT $6.00
- AVG Volume (30 Days)
- TNYA 2.3M
- GALT 1.5M
- Earning Date
- TNYA 08-07-2025
- GALT 08-12-2025
- Dividend Yield
- TNYA N/A
- GALT N/A
- EPS Growth
- TNYA N/A
- GALT N/A
- EPS
- TNYA N/A
- GALT N/A
- Revenue
- TNYA N/A
- GALT N/A
- Revenue This Year
- TNYA N/A
- GALT N/A
- Revenue Next Year
- TNYA N/A
- GALT N/A
- P/E Ratio
- TNYA N/A
- GALT N/A
- Revenue Growth
- TNYA N/A
- GALT N/A
- 52 Week Low
- TNYA $0.36
- GALT $0.73
- 52 Week High
- TNYA $4.06
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- TNYA 62.18
- GALT 63.30
- Support Level
- TNYA $0.58
- GALT $2.07
- Resistance Level
- TNYA $0.70
- GALT $2.36
- Average True Range (ATR)
- TNYA 0.05
- GALT 0.27
- MACD
- TNYA 0.00
- GALT -0.01
- Stochastic Oscillator
- TNYA 93.66
- GALT 61.64
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.